MONTREAL, QUEBEC -- (MARKET WIRE) -- December 11, 2006 -- MethylGene Inc. (TSX: MYG), along with its partner Pharmion Corporation (NASDAQ: PHRM), today announced clinical data from its Phase I/II combination trial with Vidaza® (Trial 005) and from a Phase I single-agent trial (Trial 004) for its isotype-selective, histone deacetylase (HDAC) inhibitor, MGCD0103, as well as a brief update for its other MGCD0103 clinical trials. The clinical data was presented at two poster sessions at the 48th Annual Meeting of the American Society of Hematology (ASH) in Orlando on Sunday, December 10th, 2006.
